Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 493-502 , July 2007

Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3

  • Huma Mohsin

      Affiliations

    • Chemistry Department, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Jonathan Fitzsimmons

      Affiliations

    • Chemistry Department, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Tiffani Shelton

      Affiliations

    • Harry S. Truman Veterans' Administration Hospital, Columbia, MO 65212, USA
    • ,
  • Timothy J. Hoffman

      Affiliations

    • Harry S. Truman Veterans' Administration Hospital, Columbia, MO 65212, USA
    • ,
  • Cathy S. Cutler

      Affiliations

    • University of Missouri Research Reactor (MURR), Columbia, MO 65211, USA
    • ,
  • Michael R. Lewis

      Affiliations

    • Harry S. Truman Veterans' Administration Hospital, Columbia, MO 65212, USA
    • Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Phillip S. Athey

      Affiliations

    • Dowpharma, The Dow Chemical Company, Freeport, TX 77541, USA
    • ,
  • Gyongyi Gulyas

      Affiliations

    • Dowpharma, The Dow Chemical Company, Freeport, TX 77541, USA
    • ,
  • Garry E. Kiefer

      Affiliations

    • Dowpharma, The Dow Chemical Company, Freeport, TX 77541, USA
    • ,
  • R. Keith Frank

      Affiliations

    • Dowpharma, The Dow Chemical Company, Freeport, TX 77541, USA
    • IsoTherapeutics Group LLC, 1004 S. Velasco, Angleton, TX 77515, USA
    • ,
  • Jaime Simon

      Affiliations

    • Dowpharma, The Dow Chemical Company, Freeport, TX 77541, USA
    • IsoTherapeutics Group LLC, 1004 S. Velasco, Angleton, TX 77515, USA
    • ,
  • Susan Z. Lever

      Affiliations

    • Chemistry Department, University of Missouri, Columbia, MO 65211, USA
    • University of Missouri Research Reactor (MURR), Columbia, MO 65211, USA
    • ,
  • Silvia S. Jurisson

      Affiliations

    • Chemistry Department, University of Missouri, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 573 882 2107; fax: +1 573 882 2754.

Received 17 July 2006 ,Revised 20 March 2007 ,Accepted 20 March 2007.

References 

  1. Lamb HM, Faulds D. Capromab pendetide: a review of its use as an imaging agent in prostate cancer. Drugs & Aging. 1998;12(4):293–304
  2. Bhattacharya S, Lahiri A. Clinical role of indium-111 antimyosin imaging. Eur J Nucl Med. 1991;18(11):889–895
  3. Bohdiewicz PJ, Scott GC, Juni JE, Fink-Bennett D, Wilner F, Nagle C, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med. 1995;20(3):230–236
  4. Rypins EB, Kipper SL, Weiland F, Neal C, Line B, McDonald R, et al. 99mTc anti-CD15 monoclonal antibody (LeuTech) imaging improves diagnostic accuracy and clinical management in patients with equivocal presentation of appendicitis. Ann Surg. 2002;235(2):232–239
  5. Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-scan and prospects for therapy. J Nucl Med Technol. 1997;25(1):18–23
  6. Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol. 2005;32:S36–S43
  7. Lewington V. Development of 131I-tositumomab. Semin Oncol. 2005;32:S50–S56
  8. Anderson CJ, Welch MJ. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev. 1999;99:2219–2234
  9. Liu S, Edwards DS. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem Rev. 1999;99:2235–2268
  10. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev. 1999;99:2269–2292
  11. Sundberg MW, Meares CF, Goodwin DA, Diamanti CI. Chelating agents for the binding of metal ions to macro molecules. Nature. 1974;250:587–588
  12. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem. 1994;5:565–576
  13. Lewis MR, Kao JY, Anderson A-LJ, Shively JE, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem. 2001;12:320–324
  14. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm. 2000;15:531–545
  15. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 2001;12:7–34
  16. Aime S, Anelli PL, Botta M, Fedeli F, Grandi M, Paoli P, et al. Synthesis, characterization, and 1/T1 NMRD profiles of gadolinium(III) complexes of monoamide derivatives of DOTA-like Ligands. X-ray Structure of 10-[2-[[2-Hydroxy-1-(hydroxymethyl)ethyl]amino]-1-[(phenylmethoxy)methyl]-2-oxo-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triaacetic acid-gadolinium(III) complex. Inorg Chem. 1992;31:2422–2428
  17. Amin S, Voss DA, Horrocks WD, Morrow JR. Restoration of catalytic activity by replacement of a coordinated amide group: synthesis and laser-induced luminescence studies of the phosphate diester transesterification catalyst [Eu(NBAC)]3+. Inorg Chem. 1996;35:7466–7467
  18. Zhang S, Kovacs Z, Burgess S, Aime S, Terreno E, Sherry AD. {DOTA-bis(amide)}lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. Chem Eur J. 2001;7:288–296
  19. Zhang S, Wu K, Sherry AD. Unusually sharp dependence of water exchange rate versus lanthanide ionic radii for a series of tetraamide complexes. J Am Chem Soc. 2002;124:4226–4227
  20. Congreve A, Parker D, Gianolio E, Botta M. Steric control of lanthanide hydration state: fast water exchange at gadolinium in a mono-amide ‘DOTA’ complex. Dalton Trans. 2004;1441–1445
  21. Zhang S, Jiang X, Sherry AD. Modulation of the lifetime of water bound to lanthanide metal ions in complexes with ligands derived from 1,4,7,10-tetraazacyclododecane tetraacetate (DOTA). Helv Chim Acta. 2005;88:923–935
  22. Stenson PA, Thompson AL, Parker D. Structural characterization of a diprotonated ligand lanthanide complex — a key intermediate in lanthanide ion association and complex dissociation pathways. Dalton Trans. 2006;3291–3293
  23. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431–442
  24. Chong HS, Garmestani K, Ma D, Milenic DE, Overstreet T, Brechbiel MW. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J Med Chem. 2002;45:3458–3464
  25. Lever SZ, Lydon JD, Cutler CS, Jurisson SS. Radioactive metals in imaging and therapy. In:  Meyer TJ editors. Comprehensive coordination chemistry II. vol. 9:London: Elsevier Ltd; 2004;p. 883–911
  26. Chappell LL, Ma D, Milenic K, Garmestani K, Venditto V, Beitzel MP, et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,Nʺ,Nʺ′-tetraacetic acid for radiolabeling proteins. Nucl Med Biol. 2003;30:581–595
  27. Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, et al. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho and 177Lu. Bioconjug Chem. 2006;17:485–492
  28. Broan CJ, Cox ASC, Kataky R, Parker D, Harrison A, Randall AM, et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of ytrrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J Chem Soc Perkin Trans. 1991;2:87–99
  29. Toth E, Brucher E, Lazar I, Toth I. Kinetics of formation and dissociation of lanthanide(III)–DOTA complexes. Inorg Chem. 1994;33:4070–4076
  30. Moreau J, Guillon E, Pierrard JC, Rimbault J, Port M, Aplincourt M. Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DOTA) — characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry. Luminescence spectroscopy, and EXAFS. Chem Eur J. 2004;10:5218–5232
  31. Colcher D, Milenic DE, Ferroni P, Roselli M, Schlom J. In vivo and In vitro clinical applications of monoclonal antibodies against TAG-72. Nucl Med Biol. 1991;18(4):395–401
  32. Schlom J, Colcher D, Roselli M, Carrasquillo JA, Reynolds JC, Larson SM, et al. Tumor targeting with monoclonal antibody B72.3. Nucl Med Biol. 1989;16(2):137–142
  33. Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS, et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 2001;28:145–154
  34. Knogler K, Grunberg J, Novak-Hofer I, Zimmermann K, Schubiger PA. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol. 2006;33:883–889
  35. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled abegrin, a humanized monoclonal antibody against integrin αVβ3. Cancer Res. 2006;66:9673–9681
  36. David Colcher, personal communication: “Unless there is evidence of aggregation, there is no alteration of RES uptake or metabolism of B72.3 as a function of chelates per antibody.”
  37. Turner A, King DJ, Farnsworth APH, Rhind SK, Pedley RB, Boden J, et al. Comparative biodistributions of indium-111-labeled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice. Br J Cancer. 1994;70:35–41
  38. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44:77–84
  39. Carney PL, Rogers PE, Johnson DK. Dual isotope study of iodine-125 and indium-111-labeled antibody in athymic mice. J Nucl Med. 1989;30(3):374–384
  40. Riesen A, Kaden TA, Ritter W, Maecke HR. Synthesis and X-ray structural characterization of seven co-ordinate macrocyclic In3+ complexes with relevance to radiopharmaceutical applications. J Chem Soc Chem Commun. 1989;460–462

PII: S0969-8051(07)00090-X

doi: 10.1016/j.nucmedbio.2007.03.006

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 493-502 , July 2007

Article Tools

* Image Usage & Resolution